Roundview Capital LLC Increases Stake in West Pharmaceutical Services, Inc. $WST

Roundview Capital LLC increased its position in West Pharmaceutical Services, Inc. (NYSE:WST) by 385.8% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 3,804 shares of the medical instruments supplier’s stock after acquiring an additional 3,021 shares during the quarter. Roundview Capital LLC’s holdings in West Pharmaceutical Services were worth $1,047,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Elyxium Wealth LLC purchased a new stake in West Pharmaceutical Services in the 4th quarter worth about $25,000. Private Trust Co. NA raised its holdings in West Pharmaceutical Services by 156.4% during the 4th quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier’s stock valued at $28,000 after acquiring an additional 61 shares during the period. International Assets Investment Management LLC bought a new stake in West Pharmaceutical Services during the 4th quarter valued at $31,000. CYBER HORNET ETFs LLC bought a new stake in West Pharmaceutical Services during the 2nd quarter valued at $25,000. Finally, Torren Management LLC bought a new stake in West Pharmaceutical Services during the 4th quarter valued at $34,000. Hedge funds and other institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Price Performance

NYSE:WST opened at $312.22 on Thursday. The firm has a market capitalization of $22.06 billion, a price-to-earnings ratio of 41.74, a P/E/G ratio of 2.65 and a beta of 1.17. West Pharmaceutical Services, Inc. has a 52-week low of $206.10 and a 52-week high of $330.88. The stock has a fifty day moving average of $280.24 and a 200 day moving average of $266.97. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.04 and a current ratio of 2.71.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.68 by $0.45. The company had revenue of $844.90 million during the quarter, compared to analyst estimates of $779.68 million. West Pharmaceutical Services had a return on equity of 19.03% and a net margin of 16.85%.The firm’s quarterly revenue was up 21.0% on a year-over-year basis. During the same quarter last year, the company earned $1.45 earnings per share. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. On average, research analysts expect that West Pharmaceutical Services, Inc. will post 8.6 EPS for the current fiscal year.

West Pharmaceutical Services declared that its board has approved a share buyback program on Tuesday, February 17th that authorizes the company to repurchase $1.00 billion in shares. This repurchase authorization authorizes the medical instruments supplier to buy up to 5.6% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s board of directors believes its shares are undervalued.

Insider Buying and Selling at West Pharmaceutical Services

In other West Pharmaceutical Services news, VP Annette F. Favorite sold 2,817 shares of the business’s stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $305.20, for a total value of $859,748.40. Following the completion of the transaction, the vice president owned 16,828 shares of the company’s stock, valued at $5,135,905.60. The trade was a 14.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Chad Winters sold 896 shares of the business’s stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $300.67, for a total transaction of $269,400.32. Following the completion of the transaction, the chief accounting officer directly owned 1,523 shares of the company’s stock, valued at approximately $457,920.41. This represents a 37.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.60% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

WST has been the topic of a number of analyst reports. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $315.00 target price on shares of West Pharmaceutical Services in a report on Friday, February 13th. Citigroup reissued a “buy” rating on shares of West Pharmaceutical Services in a report on Friday, April 24th. Barclays boosted their target price on shares of West Pharmaceutical Services from $275.00 to $310.00 and gave the company an “equal weight” rating in a report on Monday, April 27th. Evercore reissued an “outperform” rating on shares of West Pharmaceutical Services in a report on Friday, April 24th. Finally, Weiss Ratings raised shares of West Pharmaceutical Services from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, April 27th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $322.89.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.